Walsh, E, Buchanan, A, Fahy, T. Violence and schizophrenia: examining the evidence. Br J Psychiatry
2002; 180: 490–5.
Swanson, JW, Swartz, MS, Elbogen, EB. Effectiveness of atypical antipsychotic medications in reducing violent behavior among persons with schizophrenia in community-based treatment. Schizophr Bull
2004; 30: 3–20.
Buckley, PF. The role of typical and atypical antipsychotic medications in the management of agitation and aggression. J Clin Psychiatry
1999; 60: 52–60.
Buckley, PF, Bartell, J, Donenwirth, K, Lee, S, Torigoe, F, Schulz, SC. Violence and schizophrenia: clozapine as a specific antiaggressive agent. Bull Am Acad Psychiatry Law
1995; 23: 607–11.
Citrome, L, Krakowski, M, Greenberg, WM, Andrade, E, Volavka, J. Antiaggressive effect of quetiapine in a patient with schizoaffective disorder. J Clin Psychiatry
2001; 62: 901.
Taylor, PJ, Butwell, M, Gray, C, Daly, R, Delal, B, Ferraro, D, Gibb, R, Heads, T, Huckstep, B, Larkin, E, Leese, M, Shetty, G, Winton, M, Tidmarsh, D, Williams, D. Schizophrenia, violence, clozapine and risperidone: a review. Br J Psychiatry
1996; 169: 21–30.
Volavka, J. The effects of clozapine on aggression and substance abuse in schizophrenic patients. J Clin Psychiatry
1999; 60: 43–6.
Volavka, J, Czobor, P, Sheitman, B, Lindenmayer, JP, Citrome, L, McEvoy, JP, Cooper, TB, Chakos, M, Lieberman, JA. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry
2002; 159: 255–62.
Lieberman, JA, Stroup, TS, McEvoy, JP, Swartz, MS, Rosenheck, RA, Perkins, DO, Keefe, RS, Davis, SM, Davis, CE, Lebowitz, BD, Severe, J, Hsiao, JK. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med
2005; 353: 1209–23.
Jones, PB, Barnes, TRE, Davies, L, Dunn, G, Lloyd, H, Hayhurst, KP, Murray, RM, Markwick, A, Lewis, SW. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry
2006; 63: 1079–87.
Tiihonen, J, Walhbeck, K, Lonnqvist, J, Klaukka, T, loannidis, JP, Volavka, J, Haukka, J. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ
2006; 333: 224–7.
Swanson, JW, Van Dorn, RA, Swartz, MS, Smith, A, Elbogen, EB, Monahan, J. Alternative pathways to violence in persons with schizophrenia: the role of childhood antisocial behavior problems. Law Hum Behav, .
Swanson, JW, Swartz, MS, Van Dorn, RA, Elbogen, EB, Wagner, HR, Rosenheck, RA, Stroup, TS, McEvoy, JP, Lieberman, JA. A national study of violent behavior in persons with schizophrenia. Arch Gen Psychiatry
2006; 63: 490–9.
Steadman, HJ, Mulvey, EP, Monahan, J, Robbins, PC, Appelbaum, PS, Grisso, T, Roth, LH, Silver, E. Violence by people discharged from acute psychiatric inpatient facilities and by others in the same neighborhoods. Arch Gen Psychiatry
1998; 55: 393–401.
Swanson, JW, Swartz, MS, Elbogen, EB, Van Dorn, RA. Reducing violence risk in persons with schizophrenia: olanzapine vs. risperidone. J Clin Psychiatry
2004; 65: 1666–73.
Stroup, TS, McEvoy, JP, Swartz, MS, Byerly, MJ, Glick, ID, Canive, JM, McGee, MF, Simpson, GM, Stevens, MC, Lieberman, JA. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull
2003; 29: 15–31.
Monahan, J, Steadman, H (eds). Violence and Mental Disorder: Developments in Risk Assessment.
University of Chicago Press, 1994.
Link, BG, Stueve, A, Phelan, J. Psychotic symptoms and violent behaviors: probing the components of ‘threat/control override’ symptoms. Soc Psychiatry Psychiatr Epidemiol
1998; 33: s55–60.
Swanson, J, Estroff, S, Swartz, M, Borum, R, Lachicotte, W, Zimmer, C, Wagner, R. Violence and severe mental disorder in clinical and community populations: the effects of psychotic symptoms, comorbidity, and lack of treatment. Psychiatry
1997; 60: 1–22.
Farrington, DP, Loeber, R. Some benefits of dichotomization in psychiatric and criminological research. Crim Behav Ment Health
2000; 10: 100–22.
George, L, Blazer, D, Hughes, D, Fowler, N. Social support and the outcomes of major depression. Br J Psychiatry
1989; 186: 651–6.
First, MB, Spitzer, RL, Gibbon, M, Williams, JBW. Structured Clinical Interview for Axes I and II DSM–IV Disorders – Patient Edition (SCID–I/P).
Biometrics Research Department, New York State Psychiatric Institute, 1996.
Guy, W. Early Clinical Drug Evaluation (ECDEU) Assessment Manual.
National Institute of Menta Health, 1976.
Kay, SR, Fiszbein, A, Opler, LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull
1987; 13: 261–76.
Addington, D, Addington, J, Schissel, B. A depression rating scale for schizophrenics. Schizophr Res
1990; 3: 247–51.
McEvoy, JP, Aland, JJ, Wilson, WH, Guy, W, Hawkins, L. Measuring chronic schizophrenic patients attitudes toward their illness and treatment. Hosp Community Psychiatry
1981; 32: 856–8.
Swartz, MS, Wagner, HR, Swanson, JW, Stroup, TS, McEvoy, JP, Canive, JM, Miller, DD, Reimherr, F, McGee, M, Khan, A, Van Dorn, R, Rosenheck, RA, Lieberman, JA. Substance use in persons with schizophrenia: baseline prevalence and correlates from the NIMH CATIE study. J Nerv Ment Dis
2006; 194: 164–72.
Heinrichs, DW, Hanlon, ET, Carpenter, WT. The quality of life scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull
1984; 10: 388–98.
Fleiss, JL, Williams, JB, Dubro, AF. The logistic regression analysis of psychiatric data. J Psychiatr Res
1986; 20: 145–209.
Hosmer, D, Lemeshow, S. Applied Logistic Regression (2nd edn). Wiley, 2000.
Snijders, TAB, Bosker, RJ. Multilevel Analysis: An Introduction to Basic and Advanced Multilevel Modeling.
Swanson, JW. Mental disorder, substance abuse, and community violence: an epidemiological approach. In Violence and Mental Disorder: Developments in Risk Assessment (eds Monahan, J, Steadman, H): 101–36. University of Chicago Press, 1994.
Wallace, C, Mullen, PE, Burgess, P. Criminal offending in schizophrenia over a 25-year period marked by deinstitutionalization and increasing prevalence of comorbid substance use disorders. Am J Psychiatry
2004; 161: 716–27.
Hiday, VA, Swanson, JW, Swartz, MS, Borum, R, Wagner, HR. Victimization: a link between mental illness and violence?
Int J Law Psychiatry
2001; 24: 559–72.
Link, BG, Stueve, A. Psychotic symptoms and the violent/illegal behavior of mental patients compared to community controls. In Violence and Mental Disorder: Developments in Risk Assessment (eds Monahan, J, Steadman, H): 137–160. University of Chicago Press, 1994.
Mullen, PE. Schizophrenia and violence: from correlations to preventive strategies. Advan Psychiatr Treat
2006; 12: 239–48.
Swanson, JW, Borum, R, Swartz, MS, Monahan, J. Psychotic symptoms and disorders and the risk of violent behavior in the community. Crim Behav Ment Health
1996; 6: 317–38.
Swanson, JW, Swartz, MS, Essock, SM, Osher, FC, Wagner, HR, Goodman, LA, Rosenberg, SD, Meador, KG. The social-environmental context of violent behavior in persons treated for severe mental illness. Am J Publ Health
2002; 92: 1523–31.
Appelbaum, PS, Robbins, PC, Monahan, J. Violence and delusions: data from the MacArthur Violence Risk Assessment Study. Am J Psychiatry
2000; 157: 566–72.
Herrera, JN, Sramek, JJ, Costa, JF, Roy, S, Heh, CW, Nguyen, BN. High potency neuroleptics and violence in schizophrenics. J Nerv Ment Dis
1988; 176: 558–61.
Krakowski, MI, Czobor, P, Citrome, L, Bark, N, Cooper, TB. Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry
2006; 63: 622–9.
Volavka, J, Czobor, P, Nolan, K, Sheitman, B, Lindenmayer, JP, Citrome, L, McEvoy, JP, Cooper, TB, Lieberman, JA. Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol. J Clin Psychopharmacol
2004; 24: 225–8.
Nolan, KA, Volavka, J, Mohr, P, Czobor, P. Psychopathy and violent behavior among patients with schizophrenia or schizoaffective disorder. Psychiatr Serv
1999; 50: 787–92.